PLK3 is Linked with Higher Tumor Stage and Unfavorable Prognosis in Patients with Colorectal Cancer

Overview

Journal Biomark Med

Specialties Biochemistry
General Medicine

Date 2024 Apr 17

PMID 38629862

Authors

Hai Zeng

Qian Wang

Ying Xiang

Yameng Yang

Xia Tu

Hui He

Shuang Li

Weijia Zhang

Affiliations

Soon will be listed here.

Abstract

This study intended to explore the relationship of PLK3 with prognosis in patients with colorectal cancer (CRC). PLK3 positivity was detected by immunohistochemistry in 160 patients with CRC receiving surgical resection. The median tumor PLK3-positive rate was 26.5%. Tumor PLK3-positive rate was related to increased lymph node stage (p = 0.002) and tumor-node-metastasis stage (p < 0.001) of CRC. Tumor PLK3-positive rate ≥30% was related to shortened disease-free survival (p = 0.009) and overall survival (p = 0.003); tumor PLK3-positive rate ≥50% showed a stronger correlation with them (both p = 0.001), which was validated by multivariate Cox regression analyses (both p < 0.05). Tumor PLK3-positive rate ≥50% relates to increased tumor stage and unfavorable survival in patients with CRC.

Citing Articles

Development and validation of a recurrence risk assessment model for high-grade bladder cancer based on TCGA and GEO.

Wang H, Zheng Y, Zhang C, Li M Transl Cancer Res. 2024; 13(9):4973-4984.

PMID: 39430850 PMC: 11483452. DOI: 10.21037/tcr-24-256.

References

Rottmann B, Patel N, Ahmed M, Deng Y, Ciarleglio M, Vyas M . Clinicopathological significance of neutrophil-rich colorectal carcinoma. J Clin Pathol. 2021; 76(1):34-39. PMC: 10910606. DOI: 10.1136/jclinpath-2021-207702. View

Xu D, Yao Y, Lu L, Costa M, Dai W . Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha. J Biol Chem. 2010; 285(50):38944-50. PMC: 2998109. DOI: 10.1074/jbc.M110.160325. View

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Helmke C, Becker S, Strebhardt K . The role of Plk3 in oncogenesis. Oncogene. 2015; 35(2):135-47. DOI: 10.1038/onc.2015.105. View

Wang Z, He T, Lv W, Hu J . Down-regulation of FBP1 in lung adenocarcinoma cells promotes proliferation and invasion through SLUG mediated epithelial mesenchymal transformation. Transl Cancer Res. 2023; 12(2):236-246. PMC: 10007873. DOI: 10.21037/tcr-22-2200. View

Weichert W, Kristiansen G, Winzer K, Schmidt M, Gekeler V, Noske A . Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications. Virchows Arch. 2005; 446(4):442-50. DOI: 10.1007/s00428-005-1212-8. View

Ou B, Sun H, Zhao J, Xu Z, Liu Y, Feng H . Polo-like kinase 3 inhibits glucose metabolism in colorectal cancer by targeting HSP90/STAT3/HK2 signaling. J Exp Clin Cancer Res. 2019; 38(1):426. PMC: 6815449. DOI: 10.1186/s13046-019-1418-2. View

Rao H, Chen J, Li M, Xiao Y, Fu J, Zeng Y . Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients' adverse prognosis. PLoS One. 2012; 7(1):e30806. PMC: 3266280. DOI: 10.1371/journal.pone.0030806. View

10.

Siegel R, Wagle N, Cercek A, Smith R, Jemal A . Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023; 73(3):233-254. DOI: 10.3322/caac.21772. View

11.

Zheng H, Zhang G, Zhang L, Wang Q, Li H, Han Y . Comprehensive Review of Web Servers and Bioinformatics Tools for Cancer Prognosis Analysis. Front Oncol. 2020; 10:68. PMC: 7013087. DOI: 10.3389/fonc.2020.00068. View

12.

Kressin M, Fietz D, Becker S, Strebhardt K . Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer. Cells. 2021; 10(5). PMC: 8151477. DOI: 10.3390/cells10051176. View

13.

Weichert W, Denkert C, Schmidt M, Gekeler V, Wolf G, Kobel M . Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer. 2004; 90(4):815-21. PMC: 2410182. DOI: 10.1038/sj.bjc.6601610. View

14.

Xie Y, Liu Y, Li Q, Chen J . Polo-like kinase 2 promotes chemoresistance and predicts limited survival benefit from adjuvant chemotherapy in colorectal cancer. Int J Oncol. 2018; 52(5):1401-1414. PMC: 5873899. DOI: 10.3892/ijo.2018.4328. View

15.

Almuhanna R, Al-Thoubaity F, Almalki K, Algarni N, Hamad R, Makhtoum T . Clinicopathological Characteristics and Overall 5-Year Survival of Colorectal Cancer: A Retrospective Study. Med Sci (Basel). 2022; 10(3). PMC: 9396983. DOI: 10.3390/medsci10030042. View

16.

Vaughan C, Singh S, Subler M, Windle J, Inoue K, Fry E . The oncogenicity of tumor-derived mutant p53 is enhanced by the recruitment of PLK3. Nat Commun. 2021; 12(1):704. PMC: 7846773. DOI: 10.1038/s41467-021-20928-8. View

17.

Lin C, Bai S, Du T, Lai Y, Chen X, Peng S . Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer. Cancer Manag Res. 2019; 11:1517-1524. PMC: 6388943. DOI: 10.2147/CMAR.S176762. View

18.

Muniz-Bongers L, McClain C, Saxena M, Bongers G, Merad M, Bhardwaj N . MMP2 and TLRs modulate immune responses in the tumor microenvironment. JCI Insight. 2021; 6(12). PMC: 8262464. DOI: 10.1172/jci.insight.144913. View

19.

Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini M . Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets. 2020; 22(9):998-1009. DOI: 10.2174/1389450121999201117115717. View

20.

Ou B, Zhao J, Guan S, Wangpu X, Zhu C, Zong Y . Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer. Cancer Lett. 2016; 380(2):457-466. DOI: 10.1016/j.canlet.2016.07.004. View